Novo Nordisk is expanding access to its weight-loss drug Wegovy by partnering with telehealth providers Hims & Hers, Ro, and LifeMD. This follows a period of shortages, during which many patients turned to cheaper, compounded versions of the drug. The partnerships aim to seamlessly provide Wegovy to patients, with Novo Nordisk's online pharmacy, NovoCare, offering a discounted price. Hims & Hers stock surged 30% on the news, while Novo Nordisk's rose 3%. The move capitalizes on the reduction of compounded Wegovy availability due to legal restrictions.
Prepared by Olivia Bennett and reviewed by editorial team.
Comments